#chronicspontaneousurticaria — Public Fediverse posts

https://www.europesays.com/ch/135747/ Cue chalks up phase 2 hives win for Xolair challenger #biotech #ChronicSpontaneousUrticaria #ClinicalData #CueBiopharma #FierceBiotechHomepage #Roche #Xolair

https://www.europesays.com/ch/126929/ Yuhan Corporation to Handle South Korean Distribution and Sales of Novartis’ Next-Generation Blockbuster ‘Remibrutinib’ — BigGo Finance #BoehringerIngelheim #Bruton’sTyrosineKinase #ChoWookJe #ChronicSpontaneousUrticaria #Gilead #lesigercept #Novartis #NovartisKorea #remibrutinib #YuhanCorporation

https://www.europesays.com/ch/126761/ Yuhan to Distribute Novartis Hives Drug Rhapsido in Korea #BTKInhibitor #ChronicSpontaneousUrticaria #lesigercept #Novartis #NovartisKorea #remibrutinib #Rhapsido® #Yuhan

https://www.europesays.com/ch/94532/ Evommune’s phase 2b flops, ending challenge to Novartis in hives #biotech #ChronicSpontaneousUrticaria #ClinicalData #Dermatology #FailedTrials #FierceBiotechHomepage #Novartis

Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?

Sanofi’s SNY Dupixent, which it co-develops with Regeneron REGN, is its key top-line driver. The drug has transformed the treatment…
#France #FR #Europe #EU #Sanofi #approvedindications #atopicdermatitis #chronicrhinosinusitis #chronicspontaneousurticaria #Dupixent #inflammatorydiseases #Regeneron #severeasthma #ZacksInvestmentResearch
https://www.europesays.com/france/40120/

https://www.europesays.com/ch/89238/ FDA clears Novartis’ oral drug for chronic hives #ChronicSpontaneousUrticaria #ImmunologyAndInflammation #Novartis #PharmaNews #RegulatoryApproval #remibrutinib #Rhapsido®

https://www.europesays.com/ch/88223/ Novartis’ Rhapsido Meets Primary Goal in Phase III Skin Disorder Study #CholinergicUrticaria #ChronicSkinCondition #ChronicSpontaneousUrticaria #ColdUrticaria #Novartis #PrimaryEndpoint #SymptomControl #ZacksInvestmentResearch

https://www.europesays.com/ch/84703/ Novartis’ Rhapsido Meets Primary Goal in Phase III Skin Disorder Study #CholinergicUrticaria #ChronicSkinCondition #ChronicSpontaneousUrticaria #ColdUrticaria #Novartis #PrimaryEndpoint #SymptomControl #ZacksInvestmentResearch

https://www.europesays.com/ch/83803/ Novartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For Growth #Avidity #ChronicSpontaneousUrticaria #GlobalCommunity #IndividualInvestors #NeuromuscularDisease #Novartis #PipelineProgress #RNA #RocketLab

https://www.europesays.com/ch/82319/ Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) #AdultPatients #CholinergicUrticaria #ChronicHives #ChronicSpontaneousUrticaria #ColdUrticaria #EAACI #Novartis #TreatmentOption #TreatmentOptions #urticaria

https://www.europesays.com/ch/82297/ Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU) #AdultPatients #CholinergicUrticaria #ChronicHives #ChronicSpontaneousUrticaria #ColdUrticaria #EAACI #Novartis #TreatmentOption #TreatmentOptions #urticaria

https://www.europesays.com/ch/79990/ Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 #ChronicSpontaneousUrticaria #EAACI #ExtensionData #FoodAllergy #Novartis #patients #ScientificEvidence #TreatmentExperience #urticaria

https://www.europesays.com/ch/79976/ Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026 #ChronicSpontaneousUrticaria #EAACI #ExtensionData #FoodAllergy #Novartis #patients #ScientificEvidence #TreatmentExperience #urticaria

https://www.europesays.com/ch/77296/ Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria #AdultPatients #ChronicSpontaneousUrticaria #EuropeanCommission #Novartis #remibrutinib #urticaria

https://www.europesays.com/ch/76693/ Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 #AAD #ChronicDiseases #ChronicSpontaneousUrticaria #Cosentyx #DataIntegrity #DataPrivacy #EfficacyData #HidradenitisSuppurativa #Novartis #OralPresentation

A Look At Sanofi (ENXTPA:SAN) Valuation After New Dupixent Regulatory Milestones

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for…
#France #FR #Europe #EU #Sanofi #chronicspontaneousurticaria #Dupixent #totalshareholderreturn
https://www.europesays.com/france/25602/

Sanofi Expands Immunology Footprint With New Approvals And Respiratory Data

Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge. Sanofi…
#France #FR #Europe #EU #Sanofi #bispecificantibody #chronicspontaneousurticaria #Nuvaxovid #respiratorydiseases
https://www.europesays.com/france/18925/

https://www.europesays.com/ch/64392/ Novartis Weighs US Buildout And Rhapsido Launch In Growth Outlook #ChronicSpontaneousUrticaria #Europe #EuropeanCommission #Manufacturing #Novartis #ResearchFacilities #Rhapsido® #therapies

https://www.europesays.com/ch/57123/ Novartis Adds New Therapies As Shares Trade Below Analyst Value Targets #ChronicSpontaneousUrticaria #EuropeanCommission #Novartis #SharePrice #TargetedTherapy #WorldHealthOrganization

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Novartis Pharma AG Significant improvements as early as Week 1, favorable safety profile and no liver safety concerns in REMIX 1 &…
#Europe #EU #EuropeanCommission #adultpatients #chronicspontaneousurticaria #Novartis #remibrutinib #urticaria
https://www.europesays.com/europe/23666/

https://www.europesays.com/ch/43726/ Novartis Bolsters Immunology Pipeline With Excellergy Deal #AllergicAsthma #AllergicDiseases #ChronicSpontaneousUrticaria #ChronicUrticaria #ExcellergyInc #FoodAllergy #Novartis

https://www.europesays.com/ch/?p=41153 Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab #BEACONPhase #ChronicSpontaneousUrticaria #CompleteResponse #PennyStocks #therapeutics #UBS

https://www.europesays.com/ch/36921/ Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026 #AAD #ChronicDiseases #ChronicSpontaneousUrticaria #Cosentyx #DataIntegrity #DataPrivacy #EfficacyData #HidradenitisSuppurativa #Novartis #OralPresentation

Sanofi (SNY) and Regeneron’s Dupixent Recommended for EU Approval https://www.byteseu.com/1842048/ #ChronicSpontaneousUrticaria #Dupixent #Europe #FinalDecision #Sanofi

SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the treatment of…
#NewsBeep #News #Medication #antihistamines #CA #Canada #chronicrhinosinusitis #chronicspontaneousurticaria #Dupixent #EuropeanCommission #europeanunion #Health #inflammatorydiseases #Regeneron #Sanofi #severeasthma #ZacksInvestmentResearch
https://www.newsbeep.com/ca/307594/

https://www.europesays.com/uk/593972/ SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria #Antihistamines #ChronicRhinosinusitis #ChronicSpontaneousUrticaria #Dupixent #EuropeanCommission #EuropeanUnion #Health #InflammatoryDiseases #Medication #Regeneron #Sanofi #SevereAsthma #UK #UnitedKingdom #ZacksInvestmentResearch

https://www.europesays.com/ie/200303/ SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria #Antihistamines #ChronicRhinosinusitis #ChronicSpontaneousUrticaria #Dupixent #Éire #EuropeanCommission #EuropeanUnion #Health #IE #InflammatoryDiseases #Ireland #Medication #Regeneron #Sanofi #SevereAsthma #ZacksInvestmentResearch

SNY & REGN’s Dupixent Gets EU Nod for Chronic Spontaneous Urticaria

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the …
#NewsBeep #News #US #USA #UnitedStates #UnitedStatesOfAmerica #Medication #antihistamines #chronicrhinosinusitis #chronicspontaneousurticaria #Dupixent #EuropeanCommission #EuropeanUnion #Health #inflammatorydiseases #Regeneron #Sanofi #severeasthma #ZacksInvestmentResearch
https://www.newsbeep.com/us/313749/